Peptides for Fat Loss vs Weight Loss: The Difference

Fat loss is a different problem from weight loss. The STEP 1 trial (Wilding et al., NEJM 2021) showed semaglutide drops 14.9% body weight — but body composition analyses across STEP follow-ups show roughly 39% of that lost mass is lean tissue, not fat. So a 100 kg patient who loses 15 kg on semaglutide loses about 9 kg of fat and 6 kg of lean mass. That ratio explains both the visible "Ozempic face" complaint and the fast post-discontinuation regain.

Real body recomposition aims for the opposite ratio. The goal is to lose 10-15% body weight where 85%+ of the loss is fat tissue and lean mass is preserved or gains. The visible result is "smaller and fitter" rather than "smaller and deflated," and the post-protocol metabolic rate stays high enough to make regain unlikely.

Three things drive that outcome: peptides that specifically target adipocyte metabolism rather than appetite, structured resistance training, and adequate protein. Skip any of the three and the outcome reverts to scale weight loss with the standard lean-tissue cost.

Three peptide classes target fat loss with muscle preservation. Growth hormone secretagogues (CJC-1295, sermorelin, ipamorelin) raise endogenous GH pulses by 2-5x, which preferentially mobilizes fat from visceral depots while supporting lean mass synthesis. Fat-fragment peptides (AOD-9604) target lipolysis without affecting glucose or appetite. GLP-1 agonists (semaglutide) are usable for fat loss but require careful protein and training discipline to avoid the lean-tissue cost.

The cleanest body recomposition stacks combine a GH secretagogue with a lipolytic peptide and resistance training. CJC-1295 + ipamorelin twice weekly raises 24-hour GH output and IGF-1 by roughly 20-30%, which signals lean mass preservation while accelerating fat oxidation. Adding AOD-9604 mornings provides marginal additional fat-specific signal during the caloric deficit window.

The trade-off versus pure GLP-1 protocols is slower scale-weight movement. Expect 0.3-0.5% body weight per week on a recomposition stack versus 0.7-1.0% per week on semaglutide. The visible body composition change at 12 weeks is often more dramatic on the recomposition stack despite less scale movement.

Body composition response to peptides is heavily genetic. Three SNP clusters matter most:

• PPARG rs1801282 (Pro12Ala) — peroxisome proliferator-activated receptor gamma. The Ala allele predicts better insulin sensitivity and faster fat mobilization on GH secretagogues. Pro/Pro homozygotes (most common variant) show weaker response and may benefit more from GLP-1 approach.
• ADRB3 rs4994 (Trp64Arg) — beta-3 adrenergic receptor. This is the receptor AOD-9604 depends on. Trp/Trp carriers have normal thermogenic response. Arg-allele carriers show 30-40% reduced beta-3 signaling and weaker response to lipolytic peptides — they need to lean harder on GH secretagogues or GLP-1.
• FTO rs9939609 — fat-mass and obesity-associated gene. The A-allele predicts higher baseline appetite and stronger response to dietary protein loading + GLP-1 stacks. Carriers benefit more from semaglutide-anchored protocols.
• GHR (growth hormone receptor) variants — affect tissue sensitivity to elevated GH. Predict whether CJC-1295 + ipamorelin will produce dramatic recomposition or marginal effects.

A genetic-matched protocol picks the lever that fits the bottleneck. If your DNA shows ADRB3 Arg-allele (weak beta-3 signaling), AOD-9604 will likely underperform — your time is better spent on CJC-1295 + ipamorelin or a GLP-1-anchored stack. If your DNA shows PPARG Ala-allele plus normal ADRB3, the GH secretagogue path produces the cleanest recomposition.

Semaglutide body composition data (Volpe et al., Diabetes Obes Metab 2023). DEXA analysis of STEP 1 subset showed 39% of weight lost was lean mass when patients were not on a structured resistance program. Patients in protocols mandating 1.6+ g/kg protein and 3x weekly resistance training saw lean mass loss drop to 18-22%.

CJC-1295 GH amplification (Teichman et al., J Clin Endocrinol Metab 2006). 1 mg subcutaneous in healthy adults raised mean 24-hour GH levels 2-10x with IGF-1 increases of 1.5-3x sustained over 7-14 days post-dose. The same study established the twice-weekly dosing rationale.

CJC-1295 + ipamorelin combined (Sigalos and Pastuszak, Sex Med Rev 2018). Review of practitioner data showed mean fat mass loss of 1.5-2.5% body weight over 12 weeks combined with lean mass preservation, when paired with resistance training. Not a controlled trial but the cleanest practitioner dataset available.

AOD-9604 Phase IIb (Ng et al., Obesity Research 2006). 536 obese adults. 12-week trial. AOD-9604 1 mg/day vs. placebo. Mean weight loss 2.6 kg vs. 0.8 kg. Statistically significant, clinically unimpressive. Body composition was not the primary endpoint, but secondary DEXA analysis showed favorable fat-to-lean ratio in the AOD arm.

Tesamorelin visceral fat trial (Falutz et al., NEJM 2007). Related GHRH analog. 7 mg/day in HIV-associated lipodystrophy showed 15.2% reduction in visceral adipose tissue at 26 weeks. The clearest demonstration of GH-axis activation preferentially targeting visceral fat. Mechanism transfers to CJC-1295 protocols.

If your priority is visible body composition over scale weight: CJC-1295 + ipamorelin + AOD-9604 + structured resistance training. This is the body-recomposition path. Slower scale movement but the visible change at 12 weeks is typically more dramatic than pure GLP-1 protocols.

If you have significant excess weight (>30 lb / 14 kg above target) and appetite is the main bottleneck: Semaglutide or tirzepatide. The GLP-1 path produces faster scale loss. Mandate the protein and training protocol to preserve lean mass.

If you're already lean and want to drop the last 5-10 lb of fat: CJC-1295 + ipamorelin is the cleaner choice. Semaglutide at lean body weight tends to drop too much lean mass alongside the small fat target.

If you carry the PPARG Ala-allele and normal ADRB3 (Trp/Trp): Strongest fit for GH secretagogue path. Your insulin sensitivity supports the protocol's metabolic adaptation, and your beta-3 signaling is intact for lipolytic peptides.

If you carry ADRB3 Arg-allele (reduced beta-3 signaling): AOD-9604 likely underperforms. Lean on GLP-1 or GH secretagogue paths. Match peptide to genetic bottleneck, don't pick the broken pathway.

If you have a personal or family history of cancer: Avoid GH secretagogues. AOD-9604 is the safer fat-loss peptide in this context. GLP-1 has no formal cancer contraindication but discuss with oncologist.

Standard recomposition stack. CJC-1295 1 mg subcutaneous Monday and Thursday evenings, ipamorelin 200-300 mcg subcutaneous pre-bed nightly, AOD-9604 300 mcg subcutaneous mornings on fasted days (3-5 days per week). Run 12 weeks, then 4 weeks off. Most users see meaningful change at week 8-10.

GLP-1 anchored fat loss. Semaglutide weekly with standard 16-week escalation to 2.4 mg. Mandate 1.6-2.2 g/kg protein. 3 resistance sessions per week non-negotiable. Optional add: CJC-1295 + ipamorelin for the last 8 weeks to preserve lean mass during the steepest weight-loss phase.

Timing rules that matter. Do not eat carbohydrates within 60 minutes of GH secretagogue injection — insulin blunts the GH pulse. Pre-bed timing for ipamorelin works because most people are 3-4 hours fasted by then. Take AOD-9604 first thing morning, fasted, 30 minutes before any food.

Resistance training framework. 3x/week minimum, full-body or upper-lower split. Compound lifts (squat, deadlift, bench, row, overhead press) drive 80% of lean-mass preservation. Add 10-15 g whey protein within 30 minutes of training to capitalize on the GH-elevated synthesis window.

Tracking. Scale weight is misleading on recomposition protocols — muscle gain partially offsets fat loss. Use DEXA or BIA body composition scans monthly. Track waist circumference (more sensitive to visceral fat) and progress photos under consistent lighting weekly.

Week 1-2. No visible change. CJC-1295 raises GH pulses immediately but downstream effects take 2-3 weeks. Some users report better sleep quality and morning energy from elevated GH pulses.

Week 3-4. Subtle changes. Reduced morning waist circumference, slightly better workout recovery. Scale weight may move 1-2 lb either direction (water shifts are common). Subjective effects clearer than objective ones.

Week 5-8. First real visible change. Mean fat loss 0.3-0.5% body weight per week. Lean mass preservation visible in mirror — waist tightens but arms and shoulders stay full. Sleep quality typically improves further; IGF-1 effects accumulate.

Week 9-12. Peak effect window. This is when DEXA scans show the cleanest recomposition — fat dropping, lean mass stable or slightly up. Expect cumulative fat loss of 3-5% body weight by week 12 on a clean stack with disciplined training and protein.

Week 13-16 (cycle break). Hold gains during 4-week off-cycle. Most users maintain composition if training and protein stay disciplined. Weight may bump 1-2 lb (water + glycogen rebound) but body composition stays.

Cycle 2 onward. Diminishing returns are real. Second cycle typically produces 60-70% of first-cycle effect. Third cycle 40-50%. After three cycles, take an extended break (12+ weeks) before continuing or shift to a different mechanism.

Confusing weight loss with fat loss. Semaglutide alone drops scale weight fast but ~40% of the loss is lean tissue without resistance training. Patients who hit their scale goal but skipped the training look gaunt and regain quickly. The protocol choice depends on which outcome you actually want.

Carb-loading too close to GH secretagogue injection. Eating high-carb within 60 minutes of CJC-1295 + ipamorelin blunts the GH pulse 50-80%. The peptide is still active but the practical effect is wasted. Inject pre-bed when you're already 3+ hours fasted.

Stacking AOD-9604 with semaglutide same-day. Both peptides target metabolic pathways with overlapping signaling. Same-day dosing has not been formally studied but anecdotal reports suggest blunted effect of both. If using both, space by 8+ hours.

Ignoring protein. 1.6-2.2 g/kg is the floor for muscle preservation during weight loss. 0.8 g/kg (the standard RDA) is for sedentary people maintaining weight — wildly inadequate during a caloric deficit. Patients who skip the protein target lose lean mass regardless of which peptide is on board.

Stopping the resistance training during the cut. "I'll restart lifting once I'm leaner" is the most common path to a 6-month plateau. Lean mass without training stimulus disappears within 8-12 weeks even with high protein. Train through the cut — slightly lighter weights are fine, but volume and frequency must continue.

Running CJC-1295 + ipamorelin continuously without cycling. Receptor downregulation is real. Twelve weeks on without a break produces measurably weaker pulse response by week 10. Cycle 12 on / 4 off preserves effect across the year.

CJC-1295 + ipamorelin. Generally well-tolerated. Common: mild water retention (especially first 2 weeks), occasional injection-site reactions. Less common: numbness/tingling in extremities (carpal tunnel-like, dose-related), elevated fasting glucose at higher doses, mild headaches. Long-term safety data >12 months is limited.

AOD-9604. Phase IIb trial safety data was clean. Most common: injection site reactions. No significant glucose or insulin effects (the compound was specifically designed to remove these). No cardiovascular signal in the trial population.

Semaglutide. See weight-loss page for full safety profile. Same precautions apply: GI side effects, gallbladder signal, boxed thyroid C-cell warning, pregnancy contraindication.

Monitoring. Baseline + 12-week labs: fasting glucose, HbA1c, IGF-1, CBC, CMP. Stop the protocol if IGF-1 exceeds 350 ng/mL (upper limit of normal range) — this is the practical signal of excessive GH stimulation. Some practitioners track HbA1c during long GH secretagogue cycles as a sensitivity check.

Contraindications. Active or history of cancer (GH and IGF-1 can theoretically accelerate tumor growth — though clinical evidence is mixed). Active proliferative diabetic retinopathy. Pregnancy or active conception attempts. Significant prior history of carpal tunnel syndrome.